Advertisement

Search Results

Advertisement



Your search for The ,The matches 35314 pages

Showing 201 - 250


skin cancer

Use of Cemiplimab as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma

The randomized phase III C-POST trial attempted to learn whether the standard-of-care treatment in advanced cutaneous squamous cell carcinoma—cemiplimab-rwlc, which blocks the PD-1/PD-L1 pathway—could reduce recurrence after definitive local therapy for patients who had high-risk features....

colorectal cancer
genomics/genetics

Clinical Utility of Including ctDNA Monitoring in Standard-of-Care CRC Surveillance

Arvind N. Dasari, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses data presented at the ESMO Gastrointestinal Cancers Congress 2025, which showed that adding circulating tumor DNA (ctDNA) testing to current standard of care surveillance for patients with colorectal cancer...

genomics/genetics

MRD Testing: Recent Data and Ongoing Efforts

Circulating tumor DNA has many roles in cancer treatment: early diagnosis, tumor profiling, determining response to therapy, and tracking clinical dynamics. In this video, Arvind N. Dasari, MD, MS, of The University of Texas MD Anderson Cancer Center, focuses on it as a marker for measurable...

prostate cancer

Does Preexisting Depression Impact Prostate Cancer Survival?

Based on the results of an analysis reported in JAMA Network Open by Zhang et al, preexisting depression is associated with an increased risk of mortality from prostate cancer. The investigators commented, “Approximately one in six patients with prostate cancer experience major depression, a...

gynecologic cancers

Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

In a phase II study (ENGOT-OV60/GOG-3052/RAMP 201) reported in the Journal of Clinical Oncology, Banerjee et al evaluated the efficacy and safety of the RAF/MEK clamp avutometinib in combination with the FAK inhibitor defactinib in patients with recurrent low-grade serous ovarian cancer. Study...

lung cancer

Updated CHEST Guidelines Emphasize Minimally Invasive Surgery for Early-Stage NSCLC

Updated clinical guidelines for the management of patients with early-stage non–small cell lung cancer (NSCLC) from the American College of Chest Physicians (CHEST) recommend use of more minimally invasive procedures and methods where possible. The guidelines, published in the journal CHEST,...

LLS Unveils Name Change

The Leukemia & Lymphoma Society (LLS), the global nonprofit in funding blood cancer research, patient support, and advocacy, is becoming Blood Cancer United on August 28, in advance of Blood Cancer Awareness Month in September.   For more than 75 years, LLS has been committed to reaching and...

head and neck cancer

Perioperative Pembrolizumab Plus Surgery and Risk-Adapted Standard Adjuvant Therapy Shows Benefit in Locally Advanced Head and Neck Cancer

Earlier this year, the first interim analysis of the phase III KEYNOTE-689 trial showed that the use of the PD-1 inhibitor pembrolizumab as part of a perioperative treatment regimen with standard-of-care surgery plus adjuvant radiotherapy (with or without cisplatin alone) improved event-free...

head and neck cancer

Cannabis Use Disorder and Risk of Oral Cancer

Cannabis use disorder was associated with at least a threefold increase in the risk for developing oral cancer over 5 years compared with those without cannabis use disorder, according to findings from a multicenter clinical cohort analysis published in Preventive Medicine Reports.  “Cannabis smoke ...

issues in oncology
supportive care

FIGO Releases Best Practice Advice on Cancer During Pregnancy

The International Federation of Gynecology and Obstetrics (FIGO) has released a best practice guideline addressing cancer in pregnancy, a condition with limited data and complex diagnostic challenges. This new guidance—published by Nanda et al in the International Journal of Gynecology &...

health-care policy

Study Shows Increased Prescribing After Accelerated vs Regular Approval of Cancer Drugs

A cross-sectional study of cancer drug indications granted accelerated approval, which was published in JAMA Network Open, found that prescribing increased more after accelerated approval than after conversion to regular approval. Parikh et al also noted that off-label prescribing after accelerated ...

skin cancer

Pembrolizumab and De-escalation of Treatment in Resectable Cutaneous Squamous Cell Cancer

In an Australian phase II trial (De-Squamate) reported in the Journal of Clinical Oncology, Ladwa et al found that the use of pembrolizumab produced a high rate of clinical or pathologic complete response in patients with resectable cutaneous squamous cell cancer (cSCC), suggesting the potential to ...

genomics/genetics

LLM Trained on Somatic Mutations Shows Prognostic and Predictive Utility

Large language models (LLMs) can be trained to understand how each patient’s somatic mutations impact their cancer prognosis and possible response to therapy, according to a presentation at the AACR Special Conference in Cancer Research: Artificial Intelligence and Machine Learning. John-William...

leukemia

Acute Myeloid Leukemia With RUNX1::RUNX1T1 Fusion

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, explore the impact of the prognostic marker RUNX1::RUX1T1 fusion on the diagnosis and treatment of...

breast cancer

AI Enhances Detection of Missed Breast Cancers on Screening Tomosynthesis

A U.S. Food and Drug Administration (FDA)–cleared artificial intelligence (AI) algorithm was able to detect and correctly localize almost one-third of interval breast cancers in a retrospective evaluation of screening digital breast tomosynthesis (DBT), findings published in Radiology showed. The...

hepatobiliary cancer

Three in Five Liver Cancer Cases May Be Due to Preventable Risk Factors, The Lancet Commission Finds

Globally, three in five liver cancer cases may be due to preventable risk factors, and obesity-linked cases of the disease are on the rise, according to findings from The Lancet Commission on hepatocellular carcinoma. The majority of liver cancer cases could be prevented by reducing levels of viral ...

prostate cancer

Final Overall Survival Analysis in HRR-Deficient Cohort in TALAPRO-2: Addition of Talazoparib to Enzalutamide in Metastatic CRPC

As reported in The Lancet by Fizazi et al, the final overall survival analysis in the homologous recombination repair (HRR)-deficient metastatic castration-resistant prostate cancer (CRPC) cohort of the phase III TALAPRO-2 trial showed a significant benefit with the addition of talazoparib to...

prostate cancer

Addition of Talazoparib to Enzalutamide in Metastatic CRPC in Genetically Unselected Cohort

As reported in The Lancet by Agarwal et al, the final overall survival analysis of the phase III TALAPRO-2 trial showed that the addition of talazoparib to enzalutamide resulted in a significant benefit in a cohort of patients with metastatic castration-resistant prostate cancer (CRPC) unselected...

head and neck cancer

Similar Efficacy, Improved Safety Achieved Without Concurrent Cisplatin for Locoregionally Advanced Nasopharyngeal Cancer

The PD-1 inhibitor toripalimab in combination with an induction chemoradiotherapy regimen free of concurrent cisplatin demonstrated noninferior efficacy and superior safety compared with the same regimen plus concurrent cisplatin in patients with high-risk, locoregionally advanced nasopharyngeal...

gastroesophageal cancer

Esophageal Adenocarcinoma Recurrence Patterns With Perioperative Chemotherapy vs Preoperative Chemoradiotherapy

In an analysis from the German phase III ESOPEC trial reported in the Journal of Clinical Oncology, Hoeppner et al found that perioperative chemotherapy reduced distant recurrence vs preoperative chemoradiotherapy in patients with nonmetastatic esophageal adenocarcinoma. The primary analysis of the ...

lung cancer

Extended Outcomes With Addition of Sugemalimab to First-Line Chemotherapy in Metastatic NSCLC

In a 4-year follow-up of the Chinese phase III GEMSTONE-302 trial reported in The Lancet Oncology, Zhou et al examined the survival benefit of adding the PD-L1 inhibitor sugemalimab to first-line platinum-based chemotherapy in patients with metastatic non–small cell lung cancer (NSCLC) with no...

issues in oncology

ACS Study Finds Firefighters Face Increased Cancer Risk and Mortality, Especially for Skin and Kidney Cancers

According to the International Association of Fire & Rescue Services, there are more than 15 million firefighters protecting the inhabitants of 60 countries around the world. And while hazardous exposures from fires encountered by firefighters vary, potential risks include several known or...

breast cancer
gynecologic cancers
colorectal cancer

Study Finds Racial and Economic Segregation May Impact Advanced-Stage Breast and Cervical Cancer Diagnoses

Despite advances in early cancer detection, racial and ethnic minority individuals seem to be more likely to have a late-stage diagnosis of cancers that have a recommended screening. A large study by the American Cancer Society that examined the association between neighborhood-level segregation...

hepatobiliary cancer

STRIDE in Unresectable HCC: 5-Year Overall Survival Results From HIMALAYA

A recent exploratory analysis of the phase III HIMALAYA trial involving patients with unresectable hepatocellular carcinoma (HCC) has shown that 1 in 5 participants (19.6%) treated with the STRIDE regimen (single tremelimumab regular interval durvalumab) remained alive after 5 years of follow-up vs ...

colorectal cancer

Reevaluating Pathologic Complete Response as a Surrogate for Survival in Rectal Cancer

As reported in JAMA Network Open by Sugumar et al, a systematic review and meta-analysis of randomized clinical trials comparing neoadjuvant therapies in rectal cancer showed no trial-level association between pathologic complete response and survival. “Our study’s findings suggest a recommendation ...

solid tumors

Standard DNA Testing May Miss Majority of NUT Carcinomas, Study Finds

When a NUT carcinoma is detected, standard-of-care DNA next-generation sequencing (NGS) may be unable to detect upward of 75% of incidences of the disease, according to findings published in Clinical Cancer Research. The study authors suggested that to correctly detect and diagnosis NUT carcinomas, ...

cns cancers

Case 3: High-Grade Astrocytoma

This is Part 3 of Personalizing Therapy for Patients With Glioma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Nimish Mohile, Stephen Bagley, and Yoshie Umemura discuss the treatment of a patient with low-grade glioma. The...

cns cancers

Case 2: Low-Grade Glioma

This is Part 2 of Personalizing Therapy for Patients With Glioma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Nimish Mohile, Stephen Bagley, and Yoshie Umemura discuss the treatment of a patient with low-grade glioma. The...

cns cancers

Case 1: Low-Grade Oligodendroglioma

This is Part 1 of Personalizing Therapy for Patients With Glioma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Nimish Mohile, Stephen Bagley, and Yoshie Umemura discuss the treatment of a patient with low-grade...

hematologic malignancies
health-care policy

The Inflation Reduction Act and Ibrutinib

In August 2024, the Centers for Medicare & Medicaid Services (CMS) announced a negotiated price for the Bruton’s tyrosine kinase inhibitor ibrutinib that is 38% lower than the manufacturer’s list price. This new price will go into effect in January 2026. Negotiations began following passage...

hepatobiliary cancer

Case 3: Fibrolamellar Hepatocellular Carcinoma

This is Part 3 of First-Line Systemic Treatment of Advanced Hepatobiliary Cancers, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Laura Goff, Kristen Spencer, and Mark Yarchoan discuss the treatment of fibrolamellar...

hepatobiliary cancer

Case 2: Advanced Hepatocellular Carcinoma

This is Part 2 of First-Line Systemic Treatment of Advanced Hepatobiliary Cancers, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Laura Goff, Kristen Spencer, and Mark Yarchoan discuss the treatment of advanced hepatocellular...

hepatobiliary cancer

Case 1: Metastatic Cholangiocarcinoma

This is Part 1 of First-Line Systemic Treatment of Advanced Hepatobiliary Cancers, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Laura Goff, Kristen Spencer, and Mark Yarchoan discuss the treatment of metastatic...

lung cancer

Update to ASCO Living Guideline for NSCLC Without Driver Alterations Includes First Comparison of Immunotherapy Options

ASCO has issued a new update to its living guideline regarding therapy for stage IV non–small cell lung cancer (NSCLC) without driver alterations, based on results of three studies published recently.1 The update (the first since a previous version in February 2025) includes discussion of...

lung cancer

Studies on EGFR Mutations and NRG1 Fusions Included in ASCO NSCLC Living Guideline Update

ASCO has issued a new update to its living guideline on treatment of stage IV non–small cell lung cancer (NSCLC) with driver alterations based on two recent studies.1 The update, which amends the most recent version published in February 2025, includes a discussion of osimertinib therapy options in ...

pancreatic cancer

Surviving Pancreatic Cancer

I’ve been blessed to have remained healthy for most of my life. In fact, I can’t remember ever spending a night in the hospital until I was diagnosed with pancreatic cancer, at age 86, in the summer of 2024. And even then, the symptoms that drove me to seek care in the emergency room of my local...

breast cancer

Does Menopausal Hormone Therapy Increase the Risk of Death in Women With BRCA-Mutated Breast Cancer?

The risk of death does not appear to increase with the use of menopausal hormone therapy in women with early-onset, BRCA-mutated breast cancer who began hormone supplementation after diagnosis, based on preliminary data presented during the 2025 ASCO Annual Meeting.1 “Management of early surgical...

issues in oncology

Realizing the Full Potential of Patient Engagement in Clinical Research

Nothing about us without us is a centuries-old value that is a cornerstone of meaningful patient engagement in clinical research. Such engagement has not been automatic and is still largely absent in geriatric oncology research, where older patients traditionally have been excluded from clinical...

lung cancer

Patients With Interstitial Lung Disease Face Elevated Lung Cancer Risk, Study Finds

A large prospective cohort study conducted by Ye and Kang et al and published in JAMA Network Open found that, after adjusting for familial and other cancer-related factors, interstitial lung disease (ILD) was associated with an increased risk of developing most histologic subtypes of lung cancer....

lung cancer

Does Exposure to Wildfire-Dominated, Inhalable, Fine Particulate Matter Impact Survival in NSCLC?

Higher ambient exposure to a type of inhalable, fine particulate matter was found to be associated with an increased risk of cancer-related death for patients who were diagnosed with non–small cell lung cancer (NSCLC) while living in California—a state where wildfires are becoming more prevalent,...

cns cancers

Patritumab Deruxtecan Shows Efficacy in Leptomeningeal Metastases From Solid Tumors

The HER3-directed antibody-drug conjugate patritumab deruxtecan demonstrated clinical efficacy in treating patients with leptomeningeal metastatic disease of solid tumors, according to findings from a cohort of the phase II TUXEDO-3 trial. Researchers were also encouraged by the intracranial...

lymphoma

Fertility Outcomes in Patients of Childbearing Potential Receiving First-Line Therapy for Advanced Lymphoma

In an analysis reported in The Lancet Oncology, Ferdinandus et al found that among patients with newly diagnosed advanced-stage classical Hodgkin lymphoma who were of childbearing potential (POCBP) in the phase III HD21 trial, those receiving BrECADD (brentuximab vedotin, etoposide,...

breast cancer
survivorship

Intense Resistance Training for Breast Cancer Survivors With Lymphedema Risk

Resistance training can provide many benefits, including increased muscle mass; decreased adipose tissue; and improved metabolism, bone density, strength, and mobility. However, data are limited on the association between resistance training and the development or exacerbation of lymphedema, a...

ASTRO Announces New President-Elect, Officers

The members of the American Society for Radiation Oncology (ASTRO) recently elected four new officers to ASTRO’s Board of Directors: Catheryn M. Yashar, MD, FASTRO, President-Elect Jonathan Strauss, MD, MBA, Secretary/Treasurer-Elect Anita Mahajan, MD, FASTRO, Health Policy Council Vice Chair...

breast cancer

Immunotherapy Combination: A Potential New Standard in Triple-Negative Breast Cancer

In the phase III ASCENT-04/KEYNOTE-D19 trial, the combination of the TROP2-directed antibody-drug conjugate sacituzumab govitecan-hziy plus the PD-1 inhibitor pembrolizumab in previously untreated patients with PD-L1–positive advanced triple-negative breast cancer significantly reduced the risk of...

issues in oncology

Medicare Advantage Audits Are Expanding

Continuing its efforts to reduce fraud, waste, and abuse in Medicare, the Centers for Medicare & Medicaid Services (CMS) has announced plans to significantly enhance Risk Adjustment Data Validation (RADV) auditing in Medicare Advantage. Beginning immediately, CMS will audit all eligible...

gynecologic cancers

Case 3: Low-Grade Platinum-Resistant Ovarian Cancer

This is Part 3 of Targeted Treatment Options in Platinum-Resistant Ovarian Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Oladapo Yeku, Fernanda Musa, and Ying Liu discuss the treatment of low-grade platinum-resistant...

hematologic malignancies

Updates in Systemic Light-Chain Amyloidosis

Systemic amyloid light-chain (AL) amyloidosis is characterized by the deposition of immunoglobulin light chains, produced by clonal CD38-positive plasma cells, as insoluble amyloid fibrils in vital organs. It is a disease that can progress rapidly and is fatal without treatment. The past decade...

gynecologic cancers

Case 2: HER2-Positive Platinum-Resistant Ovarian Cancer

This is Part 2 of Targeted Treatment Options in Platinum-Resistant Ovarian Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Oladapo Yeku, Fernanda Musa, and Ying Liu discuss the treatment of HER2-positive...

gynecologic cancers

Case 1: FRα-Positive, High-Grade, Platinum-Resistant Ovarian Cancer

This is Part 1 of Targeted Treatment Options in Platinum-Resistant Ovarian Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Oladapo Yeku, Fernanda Musa, and Ying Liu discuss the treatment of high-grade platinum-resistant ...

Advertisement

Advertisement




Advertisement